Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome

Diseases of the Colon and Rectum

Volumn 54, Issue 5, 2011, Pages 518-525

  Yeung, J M C ^a   Kalff, V ^a   Hicks, R J ^a   Drummond, E ^a   Link, E ^a   Taouk, Y ^a   Michael, M ^a   Ngan, S ^a   Lynch, A C ^a   Heriot, A G ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Chemotherapy; Outcomes research; PET; Rectal cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LOCAL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLISM; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PROGNOSIS; RECTUM CANCER; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT THERAPY; ARTICLE; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RECTUM TUMOR; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79957993874     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e31820b36f0     Document Type: Review

References (36)

1. Meredith KL, Hoffe SE, Shibata D. The multidisciplinary management of rectal cancer. Surg Clin North Am. 2009;89:177-215.
2. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75-81. (Pubitemid 34686453)
3. Shivnani AT, Small W Jr, Stryker SJ, et al. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007;193:389-394.
4. Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002;45:895-903. (Pubitemid 34761469)
5. Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37:1959-1985.
6. De Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50(suppl 1):43S-54S.
7. Shin SS, Jeong YY, Min JJ, Kim HR, Chung TW, Kang HK. Preoperative staging of colorectal cancer: CT vs. integrated FDG PET/CT. Abdom Imaging. 2008;33:270-277. (Pubitemid 351537885)
8. Yeung JM, Ferris N, Lynch AC, Heriot AG. Preoperative staging of rectal cancer. Future Oncol. 2009;5:1295-1306.
9. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:180-204.
10. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192.
11. Duong CP, Hicks RJ, Weih L, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33:770-778. (Pubitemid 43979684)
12. Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys. 2009;74:60-66.
13. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18) F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605-1613. (Pubitemid 33131318)
14. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124-5130.
15. Berardi R, Maccaroni E, Onofri A, et al. Multidisciplinary treatment of locally advanced rectal cancer: aliterature review. Part 1. Expert Opin Pharmacother. 2009;10:2245-2258.
16. Moreno García V, Cejas P, Blanco Codesido M, et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2009;24:741-748.
17. Debucquoy A, Goethals L, Libbrecht L, et al. Molecular and clinico-pathological markers in rectal cancer: a tissue microarray study. Int J Colorectal Dis. 2009;24:129-138.
18. Gosens MJ, van Krieken JH, Marijnen CA, et al. Cooperative Clinical Investigators and the Pathology Review Committee. Improvement of staging by combining tumor and treatment parameters: the value for prognostication in rectal cancer. Clin Gastroenterol Hepatol. 2007;5:997-1003. (Pubitemid 47127021)
19. Gosens MJ, Dresen RC, Rutten HJ, et al. Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours. Ann Oncol. 2008;19:2026-2032.
20. Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57-64. (Pubitemid 351976386)
21. Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:665-677. (Pubitemid 40247960)
22. Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9:90-101. (Pubitemid 40037876)
23. Heriot AG, Tekkis PP, Darzi A, Mackay J. Surgery for local recurrence of rectal cancer. Colorectal Dis. 2006;8:733-747. (Pubitemid 44541701)
24. Janssen MH, Ollers MC, van Stiphout RG, et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol. 2010;94:151-155.
25. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191-200.
26. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583-1593. (Pubitemid 47476915)
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
28. Hoffmann KT, Rau B, Wust P, et al. Restaging of locally advanced carcinoma of the rectum with MR imaging after preoperative radio-chemotherapy plus regional hyperthermia. Strahlenther Onkol. 2002;178:386-392. (Pubitemid 34665786)
29. Rau B, Hänerbein M, Barth C, et al. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. Surg Endosc. 1999;13:980-984. (Pubitemid 29471358)
30. Herbertson RA, Scarsbrook AF, Lee ST, Tebbutt N, Scott AM. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol. 2009;64:225-237.
31. Kalff V, Duong C, Drummond EG, Matthews JP, Hicks RJ. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14-22. (Pubitemid 46768507)
32. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer [published online ahead of print August 25, 2009]. Ann Surg. 2009;250:582-589. doi: 10.1097/SLA.0b013e3181b91e63.
33. Davey K, Heriot AG, Mackay J, et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum. 2008;51:997-1003.
34. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87:392-399.
35. Habr-Gama A, Perez RO. Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br J Surg. 2009;96:125-127.
36. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum. 2008;51:10-20.